Chairman and Chief Executive Officer, Crispr Therapeutics
Search every verified Samarth Kulkarni interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics, has publicly discussed the company's progress in gene editing, particularly following the FDA approval of a sickle cell disease treatment developed with Vertex Pharmaceuticals. In interviews, Kulkarni described the approval as a "watershed moment in the history of biomedicine" and noted that it marked the first time humans have modified their own genome to potentially cure a disease. He has also discussed the company's broader pipeline, including programs targeting rare forms of cancer, type 2 diabetes, and autoimmune diseases like lupus, while acknowledging challenges such as delivering therapies to specific organs. Kulkarni has expressed optimism about the future of gene editing, predicting that cell and gene therapies could constitute a significant portion of the biopharma market in the coming years. He has emphasized the scalability of CRISPR technology and the importance of manufacturing efficiency, citing the company's new facility in Framingham as an example of innovation in this area. He has also addressed regulatory hurdles and the need for responsible application of the technology, distinguishing between somatic cell editing and germline editing, and has stated that the company aims to make therapies accessible to thousands of patients.
Samarth Kulkarni, Crispr Therapeutics CEO, joins 'Power Lunch' to discuss the hurdles to getting rare disease drugs through regulation, what consumers can look forward to in gene editing, and much more.
Gbola Amusa, M.D., Partner, Chief Scientific Officer, Chardan (Moderator) Samarth Kulkarni, Ph.D., CEO, CRISPR Therapeutics Andrew Obenshain, CEO, bluebird bio
Samarth Kulkarni, CRISPR Therapeutics CEO, joins 'Closing Bell Overtime' to talk winning FDA approval in the U.S. for sickle cell treatment in partnership with Vertex.
Samarth Kulkarni, PhD, CEO of CRISPR Therapeutics, joins the show to chronicle his journey to CRISPR Therapeutics and to break down the ins-and-outs of the technology; what some have called the true future of healthcare technology, and it's here. Sam begins by sharing the evolution of CRISPR as a “molecular scissors barcode” and it’s first viable indication; how he “bets” the technology will have a major footprint in the cancer, diabetes, and cardiovascular disease treatment landscapes; shares strategies for shortening the time to market for some of the products; explains how AI is used in hi…
Today, 20 years after we sequenced the first human genome, we’re starting to see the fruits of genomics. Instead of treating symptoms, researchers are focused on finding cures for once chronic and fatal diseases. We’re starting to reimagine medicine in ways previously thought impossible. This week on the For Your Innovation Podcast, we’re joined by Dr. Samarth Kulkarni, Chief Executive Officer of CRISPR Therapeutics. Sam joined CRISPR in early 2015 as Chief Business Officer. Two years later, in 2017, he was appointed to CEO. In addition to his expertise in biotech strategy and operations, Sam…
Please like, subscribe and comment. It helps our channel and community. 🧡 The mission of this channel is to raise awareness on gene-editing (and genomics in general) to investors. 🖤 💙Shop on Amazon for great discounts 💙: https://amzn.to/3dmp542 💚Paypal💚: https://paypal.me/GalaxyTutors?locale... 📚Books📚: 🧬The Code Breaker🧬: https://amzn.to/3uKLpLH Cryptocurrencies ₿ & Finances: 💳Coinsquare💳: https://coinsquare.com/register?r=c30Fm 🐺Shakeapp🐺: https://shakepay.me/r/06NF3PF 💲Questrade💲: https://www.questrade.com/account-sel... Disclaimer: This video is strictly for educational purposes. We do…
An interview with Samarth Kulkarni, PhD, Chief Executive Officer, CRISPR Therapeutics Unite to Prevent: Fifth International Vatican Conference Presented by: Fifth International Vatican Conference: http://vaticanconference2021.org/ The Cura Foundation: https://thecurafoundation.org/ Pontifical Council for Culture: http://www.cultura.va/ #UniteToPrevent #UniteToCure The Fifth International Vatican Conference and all related materials were made possible through the leadership and support of the Cura Foundation, the Vatican’s Pontifical Council for Culture, and all of the supporters, sp…
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 3:30 p.m. ET.
Dr. Samarth Kulkarni, CEO, Crispr Therapeutics, in conversation with The Hill's Editor-at-Large Steve Clemons. Health Reimagined: The Future of Healthcare is underwritten by the Biosimilars Forum.
Tshaka Cunningham, Associate Director, Scientific Collaboration, DIA, and Samarth Kulkarni, CEO, CRISPR Therapeutics, discuss the current status and regulatory challenges of integrating precision medicine, gene editing, and gene therapy into clinical care.
Sign in to search the full transcript archive, filter by topic, and access every quote from Samarth Kulkarni.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans